The abstract is read at the publisher; the summary is JClub's.
Benznidazole 150 mg once daily for 30 days achieved non-inferior sustained parasitological clearance through 36 months in adults with chronic Trypanosoma cruzi infection, with 94% clearance.
- Why it matters: Standard benznidazole or nifurtimox for chronic Chagas disease often causes drug-related adverse events that lead to treatment interruption, creating a need for better-tolerated regimens without losing efficacy.
- What they did: In the TESEO phase 2b open-label randomized trial in outpatient units in Bolivia, adults with indeterminate or early cardiac chronic Trypanosoma cruzi infection received benznidazole or nifurtimox shortened, extended, or halved-dose schedules; efficacy used sustained all-negative qPCR at 4–36 months.
- The result: The benznidazole 30-day group had fewer drug-related adverse events than the benznidazole 60-day standard of care (37% vs 60%; risk difference -23 percentage points), while non-inferiority was supported by a prespecified longitudinal GEE analysis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.